Clinical trial NCT01766024: Pharmacokinetics and Pharmacodynamics Study of BCD-033 Compared to Rebif® in Healthy Volunteers
Official title: International Multicenter Randomized Double-blind Crossover Study of Pharmacokinetics, Pharmacodynamics and Tolerability of BCD-033 (CJSC BIOCAD, Russia) and Rebif® (Merck Serono S.p.А., Italy) After Single Subcutaneous Administration to Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Keywords: interferon beta-1a
pharmacokinetics
pharmacodynamics
volunteers
Lead sponsor: Biocad
Sponsor class: INDUSTRY
First posted: 2013-01-11
Enrollment: 32
Sex: MALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This is a randomized double-blind crossover study of pharmacokinetics, pharmacodynamics and tolerability of BCD-033 (interferon beta-1a manufactured by CJSC BIOCAD, Russia) and Rebif® (Merck Serono S.p.A.., Italy) in healthy volunteers. The purpose of the study is to demonstrate the non-inferiority of pharmacokinetics, pharmacodynamics and tolerability parameters after single subcutaneous injection. Each dtug will be administered to each volunteer at a dose of 44 µg as a single subcutaneous injection with an interval of at least 14 days.

Detailed description: Each dtug (BCD-033 and Rebif) will be administered to each volunteer at a dose of 44 µg as a single subcutaneous injection with an interval of at least 14 days.

Eligibility criteria: Inclusion Criteria:

* Written informed consent;
* Male gender;
* Age 18 - 45 years inclusive;
* Body mass index (BMI) (18,5 - 24,99 kg/m2);
* Healthy condition proven by the volunteer's history, global assessment and laboratory analysis results:
* Absence in past medical history and at screening of clinically significant dysfunctions of circulatory, respiratory, nervous, hematopoietic, endocrine and digestive systems, liver and kidneys;
* Haematology and biochemistry tests, urinalysis and thyroid hormone analysis results are within normal limits according to standards of the study site. Screening laboratory analyses should be performed not more than 14 days before volunteer's inclusion in the study;
* Hemodynamic parameters are within normal limits: systolic blood pressure - from 100 to 139 mmHg, diastolic blood pressure - from 60 to 90 mmHg, heart rate - from 50 to 90 bpm;
* Absence of history of chronic infection (tuberculosis) and chronic inflammation;
* Absence of HIV, hepatitis B and C virus, syphilis;
* Absence of acute infections within 4 weeks before inclusion in the study;
* Absence of psychiatric disorders and other conditions that can interfere with volunteer's ability to follow the study protocol, including depression;
* Well-being (in volunteer's opinion) within 30 days before participation in the study;
* Absence of history of systematic alcohol and drug abuse;
* Ability of the volunteer, in investigator's opinion, to follow the study protocol procedures and requirements;
* Willingness of volunteers and their sexual partners of childbearing potential to use reliable contraception methods starting from 2 weeks before inclusion into the study and until 4 weeks after receiving the last dose of the investigational products. This criterion is not applicable to patients who underwent surgical sterilization. Reliable contraceptive measures include one barrier method in combination with one of the following methods: spermicides, intrauterine device or oral contraceptives used by participant's partner;
* Consent to avoid alcohol intake within 24 hours before and 8 days after each administration of the test or reference drugs;
* Consent to avoid grapefruit juice (or other products containing grapefruit) intake within 72 hours before and 8 days after each administration of the study or reference drugs.

Exclusion Criteria:

* Previous use of IFN-β1-containing medications at any time before inclusion;
* History of serious allergic reactions (anaphylaxis or multiple allergy);
* Known allergy or intolerance to interferons or any other components of study or reference drugs;
* Major surgery within 30 days before screening;
* Impossibility to install venous catheter for blood sampling (e.g. because of skin disorders at the sites of venipuncture);
* Diseases or other conditions that can interfere with the investigational drugs pharmacokinetics (e.g. chronic liver, kidney, blood, circulatory system, lung or neuroendocrine diseases, including diabetes mellitus and others);
* History of epileptic seizures;
* Regular oral or parenteral use of any medications including over-the-counter drugs, vitamins and nutritional additives within less than 2 weeks before inclusion in the study;
* Intake of medications, including over-the-counter drugs and biologically active additives that can influence hemodynamics, liver function etc. (barbiturates, omeprazole, cimetidine etc.) within less than 30 days before inclusion in the study;
* Intake of medications that influence immune status (cytokines and their inductors, glucocorticoids etc.) within less than 30 days before participation in the study;
* Smoking more than 10 cigarettes per day;
* Subjects who consume more than 10 units of alcohol per week or who have history of alcohol abuse or evidence of drug/chemical abuse (one unit of alcohol equals ½ l \[500 ml\] of beer, one glass \[200 ml\] of wine or l shot glass \[50 ml\] of spirits);
* Donation of 450 ml and more of blood or plasma within 2 months before inclusion in the study;
* Participation in other clinical studies within less than 1 month before inclusion in the study or simultaneous participation in another clinical study;
* Previous participation in this study

Primary outcomes:
measure: Area Under Concentration-time Curve (AUC) of Interferon (IFN) Beta-1a From the Moment of Drug Administration Until 48 Hours and to Infinity(AUC(0-48) and AUC(0-∞) Respectively)
timeFrame: 0 to 48 hours post-dose
measure: Cmax of Interferon Beta-1a
timeFrame: 0 to 48 hours post-dose
measure: AUC(0-168) and AUC(0-∞) of Neopterin and MxA Protein
timeFrame: 0 to 168 hours post-dose
Secondary outcomes:
measure: Тmax of Interferon Beta-1a Blood Samples Were Taken Before the Injection, Then After 15 Min, 30 Min, 45 Min, 1 Hour, 2 Hours, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours and 48 Hours.
timeFrame: 0 to 48 hours post-dose
measure: Т½ of Interferon Beta-1a Blood Samples Were Taken Before the Injection, Then After 15 Min, 30 Min, 45 Min, 1 Hour, 2 Hours, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours and 48 Hours.
timeFrame: 0 to 48 hours post-dose
measure: Кel of Interferon Beta-1a Blood Samples Were Taken Before the Injection, Then After 15 Min, 30 Min, 45 Min, 1 Hour, 2 Hours, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours and 48 Hours.
timeFrame: 0 to 48 hours post-dose
measure: Cl of Interferon Beta-1a Blood Samples Were Taken Before the Injection, Then After 15 Min, 30 Min, 45 Min, 1 Hour, 2 Hours, 3 Hours, 4 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours and 48 Hours.
timeFrame: 0 to 48 hours post-dose
measure: Cmax of Neopterin and MxA Protein Blood Samples Were Taken Before the Injection, Then After 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144 and 168 Hours.
timeFrame: 0 to 168 hours post-dose
measure: Tmax of Neopterin and MxA Protein
timeFrame: 0 to 168 hours post-dose
measure: Adverse Event (AE) and Serious Adverse Event (SAE) Incidence
timeFrame: up to Day 43
measure: AE of Garde 3-4 Incidence
timeFrame: up to Day 43
measure: Local Reaction Incidence
timeFrame: up to Day 43
measure: Study Withdrawal Rate Due to AE
timeFrame: up to Day 43
Other outcomes:
Locations:
city: St. Petersburg
country: Russian Federation
facility: City Mariin Hospital
Study officials:
affiliation: City Mariin Hospital
name: Ivan Sardaryan, PhD
role: PRINCIPAL_INVESTIGATOR
References: